Stocktoria
COMPUGEN LTD CGEN
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2000-08-01
COMPUGEN LTD statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 87.3% | 71.5% | 94.0% | 87.0% | 88.7% |
| Operating margin | 43.1% | -53.4% | -38.8% | -471.7% | -584.6% |
| Net margin | 48.6% | -51.1% | -56.1% | -449.3% | -570.0% |
| FCF margin | 43.1% | 177.6% | -107.8% | -461.2% | -383.0% |
| Return on assets | 22.6% | -12.4% | -15.5% | -35.8% | -25.9% |
| Return on equity | 34.4% | -25.9% | -28.6% | -43.4% | -32.1% |
| Current ratio | 6.56 | 5.26 | 4.36 | 7.23 | 7.21 |
| Revenue growth | 161.1% | -16.7% | 346.1% | 25.0% | 200.0% |
Source: SEC EDGAR filings · CIK 0001119774 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.